First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

<p>Abstract</p> <p>Background</p> <p>DepoVax<sup>TM</sup> is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presente...

Full description

Bibliographic Details
Main Authors: Berinstein Neil L, Karkada Mohan, Morse Michael A, Nemunaitis John J, Chatta Gurkamal, Kaufman Howard, Odunsi Kunle, Nigam Rita, Sammatur Leeladhar, MacDonald Lisa D, Weir Genevieve M, Stanford Marianne M, Mansour Marc
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Journal of Translational Medicine
Subjects:
Immunotherapy
Peptide
Montanide
DepoVax<sup>TM</sup>
Online Access:http://www.translational-medicine.com/content/10/1/156

Internet

http://www.translational-medicine.com/content/10/1/156

Similar Items